Previous Article | Next Article 
Journal of Clinical Microbiology, April 2001, p. 1608-1611, Vol. 39, No. 4
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.4.1608-1611.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Cryptococcus laurentii Fungemia in a
Premature Neonate
Ming-Fang
Cheng,1,3
Christine C.
Chiou,1,3,*
Yung-Ching
Liu,3,4
Hao-Zan
Wang,1 and
Kai-Sheng
Hsieh1
Department of Pediatrics1 and
Microbiology Laboratory,4 Veterans
General Hospital-Kaohsiung, Kaohsiung, and Division of Clinical
Research, National Health Research Institutes,2
and National Yang-Ming University,3
Taipei, Taiwan
Received 14 August 2000/Returned for modification 26 November
2000/Accepted 26 January 2001
 |
ABSTRACT |
Cryptococcus spp. other than Cryptococcus
neoformans are generally considered nonpathogenic to humans.
There are only 15 case reports of disease in humans caused by
Cryptococcus laurentii infection. Underlying diseases and
predisposing risk factors seem to play an important role in these
cases. Our patient is the first case of an extremely low birth weight
infant with C. laurentii fungemia reported in the English
literature. In our case, the MIC of amphotericin B for C. laurentii was 0.25 to 1 µg/ml and the patient had a good
outcome following the administration of amphotericin B at 10 mg/kg
combined with central venous catheter removal. There will undoubtedly
be an increasing occurrence of unusual fungal infections accompanying
further advances in medicine. A high degree of suspicion and
improvements in the techniques for culture and identification will
contribute to the earlier diagnosis and treatment of unusual fungal infections.
 |
TEXT |
Cryptococcus spp. other
than Cryptococcus neoformans were previously considered
saprophytes and thought to be nonpathogenic to humans. However,
infections caused by species other than C. neoformans have
been increasingly recognized. We report a case of fungemia caused by
Cryptococcus laurentii in a premature infant in which
complete clinical resolution occurred after amphotericin B
administration and central venous catheter removal. The organism was
isolated twice from blood cultures drawn 2 days apart.
Case report.
A female newborn with a gestation age of 27 weeks
was admitted to our neonatal intensive care unit due to prematurity.
The neonate was delivered via spontaneous vaginal delivery following premature rupture of the amniotic membrane. The birth weight was 940 g, and the Apgar score was 5 after 1 min. Physical examination was significant for rapidly progressive respiratory distress, and the
patient was intubated soon after delivery and mechanically ventilated.
Chest radiography confirmed grade III respiratory distress syndrome.
Synthetic surfactant (colfosceril palmitate [Exosurf Neonatal]; Glaxo
Wellcome, Inc.) was administered with a good response, and the patient
was started on empiric antibiotic therapy with ampicillin and
gentamicin. The hemogram on admission was normal, as was screening for
toxoplasmosis, other infections, rubella, cytomegalovirus infection,
and herpes simplex virus. Initial cultures of blood and cerebrospinal
fluid (CSF)revealed no growth of bacteria or fungi.
Because of a transient worsening of the infant's ventilator settings
at day 4 of life, coupled with yellowish endotracheal secretions and
leukocytosis (absolute neutrophil count, 22,350/mm3),
broad-spectrum antibiotic therapy was continued with gentamicin replaced with ceftizoxime. The patient improved clinically, was extubated for the first time on day 9, and was placed on nasal continuous positive airway pressure. However, on day 11, increasing respiratory distress was noted, necessitating reintubation and mechanical ventilation. Chest radiography demonstrated a new right upper lung opacification. A hemogram was normal. Due to growth of
oxacillin-resistant Staphylococcus aureus in the culture of the tip of the removed endotracheal tube, antibiotic therapy was changed to ceftizoxime and teicoplanin. The patient's condition improved gradually over the next few days. On day 20, a repeat chest
X-ray was normal. The infant was extubated, and antibiotic therapy was discontinued.
On the 25th day of life, the infant appeared less active and had
occasional episodes of apnea and bradycardia. Over the following
24 h, a sepsis syndrome evolved with respiratory and circulatory
insufficiency, hypothermia, abdominal distension, leukocytosis
(white
blood cell count, 19,080/mm
3; 21% band forms), and
thrombocytopenia (platelet count, 54,000/mm
3). The infant
was started on an empirical antibiotic regimen of
ceftazidime and
teicoplanin with no appreciable clinical response.
Two sets of blood
cultures (BACTEC 860 system; Becton Dickinson,
Inc., Sparks, Md.) were
drawn on days 27 and 29. Both sets of
blood cultures were positive
72 h later and yielded the same encapsulated,
round-to-oval,
yeast-like fungus that grew at 37°C, produced urease,
had a slight
capsule, and was nonfermentative. Colonies were cream
colored and
darkened with age. The ID 32C system (bioMerieux Vitek,
Inc., St.
Louis, Mo.) was used to identify
C. laurentii by noting
the
utilization of lactose and melibiose. A negative caffeic acid
test and
absence of KNO
3 utilization reliably differentiated this
species from
C. neoformans and
C. albidus. The
MICs of amphotericin
B and fluconazole were determined by the broth
microdilution method
according to the National Committee for Clinical
Laboratory Standards
guidelines (
12). The MIC of
amphotericin B was 0.25 to 1 µg/ml,
and that of fluconazole was 4 µg/ml. A central venous line, placed
in the right cubital fossa
shortly after birth, was removed, parenteral
nutrition was temporarily
discontinued, and amphotericin B administration
was started.
Examination of CSF obtained prior to the start of
amphotericin B
administration was negative by routine bacteriology
culture, India ink
stains, and cryptococcal antigen test. The
tip of the withdrawn central
venous line was negative by routine
bacteriology culture. Therapy with
amphotericin B (initial dosage;
0.1 mg/kg/day; maximum dosage, 1 mg/kg/day; total cumulative dose,
10 mg/kg) was rapidly successful and
tolerated without nephrotoxicity.
A repeat culture of blood drawn on
the 37th day was negative,
and the infant was weaned from pressure
agents and extubated within
3 days after the start of antifungal
therapy. The remaining course
in the nursery was uneventful, and the
infant was discharged at
an age of 70 days. Regular postdischarge
follow-up for 1 year
showed age-appropriate development with no
evidence of late complications
of
fungemia.
Discussion.
Major risk factors for fungemia include
intravascular catheters, parenteral hyperalimentation, and
broad-spectrum antibiotics. Premature infants are at particularly
increased risk due to their extremely low body weight, poor nutrition,
enteral malabsorption, insufficient microbial defenses, and
underdeveloped anatomic barriers (13, 16). All of these
risk factors were present in our case.
Cryptococcosis is an infectious disease of worldwide occurrence caused
by an encapsulated, basidiomycetous, yeast-like fungus.
Cryptococci are
generally found in soil contaminated by pigeon
feces, as well as on the
surfaces of certain vegetables and in
milk from infected dairy cow
herds (
1). Cryptococci are transmitted
to humans primarily
through inhaled fomites, although direct entry
through the digestive
tract or skin can also occur. Species other
than
C. neoformans have generally been thought to be nonpathogenic
to
humans (
2,
9,
14).
Including the present report, there are a total of 15 case reports of
disease in humans caused by
C. laurentii infection,
7 of
which were of fungemia cases. These cases are summarized
in Table
1. Underlying diseases and predisposing
risk factors
seem to have played an important role in these cases.
Signs and
symptoms varied considerably according to sites of infection.
In fungemia patients, abnormal temperature and hypotension were
the
most common presentations. Measurement of cryptococcal antigen
in serum
or CSF was not reported in the majority of these cases;
however, if
reported, the results were consistently negative.
One patient died due
to the underlying disease, but the others
recovered after treatment in
these cases (
2,
4-7,
9,
10,
14,
17; V. Kremery, Jr., A. Kunova, and J. Mardiak, Letter,
Infection
25:130, 1997;
R. E. Winn, M. G. Rinaldi, M. Galbraith,
and J. H. Bower, Abstr. Annu. Meet. Am. Soc. Microbiol. 1985,
abstr. F37, p. 370, 1985). Our patient is the first case of an
extremely low birth weight
infant with
C. laurentii fungemia reported
in the English
literature.
In the clinical microbiology laboratory, the finding of a mucoid colony
is usually the first clue to the presence of cryptococci
and this
suspicion is further heightened when encapsulated, budding
yeasts are
observed on an India ink preparation of the colony.
There are 37 members of the genus
Cryptococcus, and virtually
all members
of the genus assimilate inositol, produce urease,
and are
nonfermentative. The identification of
C. laurentii
specifically
can be confirmed by using various biochemical tests, and
most
clinical laboratories use a battery of biochemical tests contained
in commercially available kits. A negative caffeic acid test,
absence
of KNO
3 utilization, and the utilization of lactose and
melibiose may differentiate
C. laurentii from other species
(
8).
Because of the limited number of reported cases, there is no validated
standard treatment for
C. laurentii infection. Prompt
removal of a central venous catheter is well documented as an
important
measure for clearing fungemia and preventing complications
(
3,
15). Correlations between in vitro antifungal susceptibility
test results and treatment outcome do not exist for
C. laurentii.
The organism was susceptible to amphotericin B in this
case and
those previously reported, with MICs ranging from 0.037 to 1 µg/ml,
but its susceptibility to fluconazole seemed to be equivocal,
with MICs ranging from 4 to greater than 64 µg/ml (
4,
6,
11,
12). We observed a favorable outcome following the
administration
of accumulative dose of 10 mg of amphotericin B per kg,
combined
with central venous catheter removal. Although we encountered
no toxicity due to amphotericin B, detailed analysis of toxicity
in
premature neonates is limited and merits more
attention.
Undoubtedly, there will be an increasing number of unusual fungal
infections concomitant with further advances in medicine,
especially in
areas involving immunosuppressive therapy, use of
corticosteroids and
antibiotics, and widespread use of central
venous catheters.
Improvements in the identification of unusual
pathogens will, in turn,
contribute to the increased recognition
of cases. However, a high
degree of suspicion, particularly in
predisposed patients, teamed with
newly developed techniques for
culture and identification, will likely
allow earlier diagnosis
and, it is hoped better treatment of such
unusual fungal
infections.
 |
ACKNOWLEDGMENTS |
We thank Andreas H. Groll, National Cancer Institute, and L. Clifford McDonald, University of Louisville Hospital, for expert discussion and review of the manuscript. We are also indebted to
Hsiu-Jung Lo and Tsai-Ling Lauderdale, National Health Research Institutes, Taipei, Taiwan, for editorial assistance.
 |
FOOTNOTES |
*
Corresponding author. Present address: Infectious
Disease Section, VA Medical Center, University Dr. C. Pittsburgh, PA
15240. Phone: (412) 688-6179. Fax: (412) 688-6950. E-mail:
chenchia{at}yahoo.com.
 |
REFERENCES |
| 1.
|
Chand-Goyal, T., and R. A. Spotts.
1996.
Enumeration of bacterial and yeast colonists of apple fruits and identification of epiphytic yeasts on pear fruits in the Pacific Northwest United States.
Microbiol. Res.
151:427-432[Medline].
|
| 2.
|
Custis, P. H.,
J. A. Haller, and E. de Juan, Jr.
1995.
An unusual case of cryptococcal endophthalmitis.
Retina
15:300-304[CrossRef][Medline].
|
| 3.
|
Dato, V. M., and A. S. Dajani.
1990.
Candidemia in children with central venous catheters: role of catheter removal and amphotericin B therapy.
Pediatr. Infect. Dis. J.
9:309-314[Medline].
|
| 4.
|
Johnson, L. B.,
S. F. Bradley, and C. A. Kauffman.
1998.
Fungaemia due to Cryptococcus laurentii and a review of non-neoformans cryptococcaemia.
Mycoses
41:277-280[Medline].
|
| 5.
|
Kamalam, A.,
P. Yesudian, and A. S. Thambiah.
1977.
Cutaneous infection by Cryptococcus laurentii.
Br. J. Dermatol.
97:221-223[CrossRef][Medline].
|
| 6.
|
Kordossis, T.,
A. Avlami,
A. Velegraki,
I. Stefanou,
G. Georgakopoulos,
C. Papalambrou, and N. J. Legakis.
1998.
First report of Cryptococcus laurentii meningitis and a fatal case of Cryptococcus albidus cryptococcaemia in AIDS patients.
Med. Mycol.
36:335-339[CrossRef][Medline].
|
| 7.
|
Kremery, V.,
I. Krupova, and D. W. Denning.
1999.
Invasive yeast infections other than Candida spp. in acute leukaemia.
J. Hosp. Infect.
41:181-194[CrossRef][Medline].
|
| 8.
|
Leslie, C.,
B. Albert, and S. Max.
1998.
Microbiology and microbial infections, vol. 4. , p. 461-473.
Arnold, London, England.
|
| 9.
|
Lynch, J. P., III,
D. R. Schaberg,
D. G. Kissner, and C. A. Kauffman.
1981.
Cryptococcus laurentii lung abscess.
Am. Rev. Respir. Dis.
123:135-138[Medline].
|
| 10.
|
Mocan, H.,
A. V. Murphy,
T. J. Beattie, and T. A. McAllister.
1989.
Fungal peritonitis in children on continuous ambulatory peritoneal dialysis.
Scott. Med. J.
34:494-496[Medline].
|
| 11.
|
Morace, G.,
S. Manzara, and G. Dettori.
1991.
In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole.
Chemotherapy
37:23-31[Medline].
|
| 12.
|
National Committee for Clinical Laboratory Standards.
1997.
Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 13.
|
Pagano, L.,
A. Antinori,
A. Ammassari,
L. Mele,
A. Nosari,
L. Melillo,
B. Martino,
M. Sanguinetti,
F. Equitani,
F. Nobile,
M. Carotenuto,
E. Morra,
G. Morace, and G. Leone.
1999.
Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes.
Eur. J. Haematol.
63:77-85[Medline].
|
| 14.
|
Ritterband, D. C.,
J. A. Seedor,
M. K. Shah,
S. Waheed, and I. Schorr.
1998.
A unique case of Cryptococcus laurentii keratitis spread by a rigid gas permeable contact lens in a patient with onychomycosis.
Cornea
17:115-118[CrossRef][Medline].
|
| 15.
|
Sadiq, H. F.,
S. Devaskar,
W. J. Keenan, and T. R. Weber.
1987.
Broviac catheterization in low birth weight infants: incidence and treatment of associated complications.
Crit. Care Med.
15:47-50[Medline].
|
| 16.
|
Saiman, L.,
E. Ludington,
M. Pfaller,
S. Rangel-Frausto,
R. T. Wiblin,
J. Dawson,
H. M. Blumberg,
J. E. Patterson,
M. Rinaldi,
J. E. Edwards,
R. P. Wenzel, and W. Jarvis.
2000.
Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group.
Pediatr. Infect. Dis. J.
19:319-324[CrossRef][Medline].
|
| 17.
|
Sinnott, J. T.,
J. Rodnite,
P. J. Emmanuel, and A. Campos.
1989.
Cryptococcus laurentii infection complicating peritoneal dialysis.
Pediatr. Infect. Dis. J.
8:803-805[Medline].
|
Journal of Clinical Microbiology, April 2001, p. 1608-1611, Vol. 39, No. 4
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.4.1608-1611.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Bialek, R., Weiss, M., Bekure-Nemariam, K., Najvar, L. K., Alberdi, M. B., Graybill, J. R., Reischl, U.
(2002). Detection of Cryptococcus neoformans DNA in Tissue Samples by Nested and Real-Time PCR Assays. CVI
9: 461-469
[Abstract]
[Full Text]